About The Company

Cortical Dynamics Ltd is an Australian Medical Device unlisted public company headquartered in Perth, Western Australia with operations in Scoresby, Victoria.

Focused on commercialising the intellectual property originally developed at Swinburne University in Melbourne. The core-product the Brain Anaesthesia Response (BARM™) System has been developed with the objective of better detecting the effect of anaesthetic agents on brain activity, aiding anaesthetists in keeping patients optimally anaesthetized.

The BAR monitoring system is based on recent innovative developments in our understanding of how the brain’s rhythmic electrical activity, EEG, is produced. This approach produces indices directly related to the physiological state of the brain, which is fundamentally different to all other currently available devices.

Directors

Ashley Zimpel

Business developer, corporate financier and investment banker with broad financial markets experience and a strong focus on innovation and business strategy. 35 year track record of founding, investing in and establishing businesses in financial capital markets, agribusiness and fintech. Held senior level positions at financial institutions and ASX listed companies including Macquarie Bank and Bankers Trust Australia.

David Breeze

Corporate finance specialist with extensive experience in the stock broking industry and capital markets. He also hold the role of Chairman of Grandbridge Ltd and BPH Energy Ltd, both ASX listed businesses.

Charles Chang

Formed Accolade, Inc. in 2000 and then Susterra EnVision in 2017, a developer of renewable energy solutions. Provides strategic advisory services to domestic/foreign corporates and private equity. Develop renewable solutions. Prior to Accolade, Managing Director at Bankers Trust. MSc. from Dartmouth and B.A. in Economics from University of California Berkeley. Served on several boards. US citizen, currently resides in Korea.

BARM™ Validation

Therapeutic Goods of Australia (TGA), CE (Europe) certified, FDA (510k approved) and Korea MFDS certified

Successfully used in over 200 operations worldwide

Key Opinion Leaders endorsement and 12 clinical publications

Received Korean audit (KGMP) approval of Cortical’s manufacturing facility at Perth, Western Australia

Extensive 29 global patent coverage including USA, Asia, Europe, ANZ

Completed or continuing trials in 12 hospitals in ANZ, Europe and UK

Winner Australian Advanced Manufacturing Technologies Competition 2016